Similarly, in NSCLC patients, the density of CD8+ CD103+ TRM cells before immunotherapy positively associates with improved outcomes and increases during the therapy in most of the responders, but not in non-responder patients [165]. This evidence concerns the gene ITGAE and non-small cell lung carcinoma.